Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Minnesota for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Minnesota only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Minnesota (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Asim Khan (NPI 1073557641)

Field	Value
Entity Type	Individual
Organization	Asim Khan
Address	9825 Hospital Dr Ste 300
City	Maple Grove
State	MN
ZIP	55369
Taxonomy	Rheumatology Physician
NPI Enumerated	June 15, 2006

Payer Source	Total Paid
Medicare	$2.4M
Medicaid	$0

Key Findings

This provider is effectively a Medicare-centered practice: lifetime Medicare revenue is $2.4M while Medicaid revenue is none (no Medicaid billing on file), indicating no recorded Medicaid activity and a single-payer (Medicare) footprint in available claims data. Analysts should treat payer-mix conclusions accordingly and not expect Medicaid comparators for in-state benchmarking.

Revenue is highly concentrated in a small number of biologic drug codes: the precomputed top 3 Medicare codes account for 79.7% of this provider's total Medicare revenue, led by J0129 ($1.2M, 49.2%), followed by J3262 ($512.8K, 20.8%) and J1602 ($237.1K, 9.6%). This concentration means that fluctuations in access, pricing, or utilization of these specific biologic infusions would materially affect the provider's Medicare revenue.

The code mix is consistent with a rheumatology practice that delivers in-office/infusion biologic therapy and procedure-based care: high-revenue injectable drugs J0129, J3262, and J1602 are paired with infusion/administration and procedural CPTs such as 96365, 96413, 20611, and arthrocentesis-related codes, indicating on-site IV/infusion workflow and point-of-care joint procedures. Combined presence of evaluation-and-management codes like 99214 and multiple ultrasound-guided arthrocentesis codes suggests longitudinal outpatient management plus procedural services.

J0129 is a national outlier for abatacept administration: this provider ranks #24 of 1221 nationally (98th percentile; extreme outlier) for J0129 volume, signaling a dominant position in delivering this specific biologic relative to peers and making abatacept a defining service line for the practice. Such extreme outlier status should be flagged for peer-competitive analyses and network contracting focused on high-cost biologic delivery.

J3262 and J1602 show elevated but more typical volumes: J3262 ranks #50 of 618 (92th percentile; typical, unremarkable volume for this code) and J1602 ranks #271 of 1041 (74th percentile; typical, unremarkable volume for this code). In plain terms, the provider is a high-volume administer of tocilizumab and golimumab relative to many peers, but these volumes are within expected national variation for practices that offer infusion biologics.

Office-visit and procedural throughput are meaningfully above typical in several areas: 99214 accounts for $69.7K (2.8%) with 774 claims and ranks in the 96th percentile (notably above typical), and 20611 accounts for $51.9K (2.1%) with 519 claims and ranks in the 97th percentile (notably above typical). These patterns indicate steady follow-up visit volume and substantial procedural activity (joint injections/arthrocentesis) supporting a procedure-forward rheumatology practice model.

Infusion and administration codes reflect an active infusion practice: 96365 (initial IV infusion) appears with 577 claims and $29.4K (1.2%) and ranks in the 97th percentile (notably above typical), while chemotherapy/infusional administration codes such as 96413 (347 claims, $35.7K, 1.5%) are present at levels characterized as typical. Together these administration codes corroborate on-site IV drug delivery capacity and recurring infusion sessions as a core operational element.

The provider has a long-established NPI: enumerated on 2006-06-15 (~20 years ago), indicating prolonged participation in Medicare and a stable billing history that supports longitudinal trend analysis and comparisons to long-tenured peers. This tenure combined with the concentrated biologic revenue base makes the provider a consistent, specialized service node in Medicare rheumatology networks.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

38 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	36,750	$30	$1.2M
J3262	Injection, tocilizumab, 1 mg	102,560	$10	$512.8K
J1602	Injection, golimumab, 1 mg, for intravenous use	21,550	$10	$237.1K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	6,720	$30	$174.7K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	770	$90	$69.7K
20611	In this procedure, the provider inserts a needle through the skin of a patient and into a major joint or bursa, typically the shoulder, hip, knee, or subacromial bursa, and then uses the syringe…	520	$100	$51.9K
J7323	Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose	460	$100	$45.1K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	350	$100	$35.7K
J7329	Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg	5,030	$10	$35.2K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	580	$50	$29.4K

Showing 1–10 of 38

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 38 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Minnesota Distribution

Asim Khan — 15 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Minnesota

Full comparison — all codes billed, vs. state median

38 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	1	20	5,330	$30	$242.9K
J3262	1	20	26,440	$1	$147.6K
J1602	3	20	7,050	$10	$112K
J1745	9	60	1,540	$30	$76.7K
J7329	2	10	5,630	$10	$39.8K
96413	14	230	70	$100	$11.5K
99214	30	10,100	70	$80	$8.1K
J7323	1	40	60	$100	$8K
20611	1	170	40	$70	$5.5K
99213	525	9,120	50	$50	$4K

Showing 1–10 of 38

Related Providers

Other providers that share a Tax Identification Number (TIN) with Asim Khan, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
North Clinic, PA	MN	Family Medicine Physician	$0	$4.5M
Moushumi Meher	MN	Family Medicine Physician	$174.9K	$0
Jerome Merkel	MN	Family Medicine Physician	$155.7K	$0
John Schaffhausen	MN	Family Medicine Physician	$91.1K	$0
David Smiley	MN	Internal Medicine Physician	$86.2K	$0
Kurt Partoll	MN	Internal Medicine Physician	$83.6K	$0
Heather Labere	MN	Family Medicine Physician	$81.2K	$0
Darrell Krieger	MN	Internal Medicine Physician	$63K	$0
Mary Broughton	MN	Medical Physician Assistant	$54.8K	$0
Mancel Mitchell	MN	Family Medicine Physician	$53.8K	$0

Nearby Providers

Other providers in the same ZIP code as Asim Khan, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Al Shifa Dentistry PA	MN	Dental Clinic/Center	$0	$18.4M
Regency Home Healthcare Services LLC	MN	Home Health Agency	$0	$11.1M
Children's Clinic Network	MN	Primary Care Clinic/Center	$0	$10M
Osseo Area Schools	MN	Local Education Agency (LEA)	$0	$8.8M
Miso Dentistry, PC	MN	Dentist	$0	$8.4M
Maple Grove Hospital Corporation	MN	General Acute Care Hospital	$0	$7.6M
Interventional Spine And Pain Physicians, PA	MN	Specialist	$0	$5.5M
North Memorial Health Care	MN	Urgent Care Clinic/Center	$0	$4.5M
Metropolitan Surgical Center, LLC	MN	Ambulatory Surgical Clinic/Center	$1.6M	$1.3M
Sumi Patel	MN	Rheumatology Physician	$364.5K	$0

Asim Khan — Billing Profile & Reimbursement Data

Sign up for Asim Khan — Billing Profile & Reimbursement Data policy alerts

Asim Khan — Billing Profile & Reimbursement Data

Sign up for Asim Khan — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References